


Amendment to the claims:

1. (Currently Amended) Compounds having the structure of Formula I:



Formula I

~~their~~ a pharmaceutically acceptable salt salts, pharmaceutically acceptable solvates, ~~enantiomers~~, ~~diastereomers~~ enantiomer, diastereomer, or N-oxide, N-oxides wherein

- 1) when X is oxygen in Formula I:

R₁ is selected from: hydrogen; alkyl; alkenyl; alkynyl; cycloalkyl; cyano; nitro; amino; substituted amino; hydroxyl; alkoxy; aryloxy; COR'; COOR'

(wherein R' can be hydrogen, alkyl, alkenyl, alkynyl, (un)saturated cycloalkyl, aryl, aralkyl, heterocyclyl, (heterocyclyl)alkyl, or (heteroaryl)alkyl);

aryl; aralkyl; heteroaryl; heterocyclyl; (heteroaryl) alkyl; (heterocyclyl) alkyl; (CH₂)₁₋₄OR'

(wherein R' is as defined above, but also including hydroxy);

C(=O)NR_xR_y

(wherein R_x and R_y can be independently selected from hydrogen, alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, (un)saturated cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl); or (CH₂)_m-C(=O)R₃ [wherein m is an integer in the range of 0-2 and R₃ can be optionally substituted R_p or R_q (wherein R_p can be a 4-12 membered (un)saturated monocyclic or bicyclic ring containing 1-4 heteroatom(s) selected from N, O and S wherein the ring can be attached to (CH₂)_mC(=O) through N and R_q can be a 4-12 membered (un)saturated monocyclic or bicyclic ring containing 0-4 heteroatom(s) selected from the group consisting of N, O and S

wherein the ring can be attached to $(CH_2)_mC(=O)$ through C) and wherein the substituents of R_3 can be one or more of: alkyl, alkenyl, alkynyl, (un)saturated cycloalkyl, halogen, hydroxyl, alkoxy, aryloxy, nitro, cyano, amino, substituted amino, hydroxyalkyl, oxo, acyl, optionally substituted amino (wherein the substituents are selected from C_1 - C_6 alkyl, aryl, aralkyl, or cycloalkyl), aryl, carboxyl, alkaryl, carbamoyl, alkyl ether, $C(=O)NR_5R_6$ (wherein R_5 and R_6 are independently selected from hydrogen, alkyl, C_{3-6} alkenyl, C_{3-6} alkynyl, aryl, and aralkyl), optionally substituted monocyclic or bicyclic 4-12 membered carbocyclic ring system (wherein the optional substituent(s) is/are selected from alkyl, alkenyl, alkynyl, halogen, hydroxyl, and alkoxy), heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl];

R_2 is selected from: cyano; heteroaryl; heterocyclyl; or $(CH_2)_nNHCOR_7$ (wherein n represents an integer 1 to 6 and R_7 can represent hydrogen, alkyl, alkenyl, alkynyl, (un)saturated, cycloalkyl, alkoxy, aryloxy, aryl, aralkyl, heteroaryl, heterocyclyl, $(CH_2)_{1-4}OR'$ wherein R' is the same as defined above, or NR_xR_y wherein R_x and R_y are the same as defined above);

R_4 is selected from: hydrogen; alkyl; halogen; cyano; carboxy; or $C(=O)NR_xR_y$ wherein R_x and R_y are the same as defined above;

X_1 and X_2 are independently selected from: hydrogen; alkyl; alkenyl; alkynyl; cycloalkyl; acyl; aryl; aralkyl; heteroaryl; heterocyclyl; (heteroaryl)alkyl; or (heterocyclyl)alkyl;

Y is selected from: an oxygen atom; a sulphur atom; or NR

(wherein R is selected from hydrogen, alkyl, alkenyl, alkynyl, un(saturated) cycloalkyl, acyl, aryl, aralkyl, heteroaryl, heterocyclyl, (heteroaryl)alkyl, or (heterocyclyl)alkyl);

Y_1 and Y_2 are independently selected from: hydrogen; alkyl; nitro; cyano; halogen; OR wherein R is the same as defined earlier; SR wherein R is the same as defined earlier; NHR wherein R is the same as defined earlier; $COOR'$; or COR' wherein R' is the same as defined above, or further, Y_1 and X_2 , X_1 and Y_2 , X_1 and X_2 may together form a ring fused with the ring A containing 3-5 carbon atoms within the ring and having 1-3 heteroatoms selected from N, O or S; and


2) when X is NR_8 or S wherein R_8 is hydrogen, lower alkyl (C_1 - C_6) or aryl:

R_1 , R_4 , X_1 , X_2 , Y , Y_1 and Y_2 are the same as defined above;

R_2 is selected from: $(CH)_nNHCOR_7$ (wherein n represents an integer 1 to 6 and R_7 is the same as defined above),

with the proviso that when R_2 is heterocyclyl, R_1 can not be $(CH_2)_{1-4}OR'$, $C(=O)NR_xR_y$ or $(CH_2)_m-C(=O)R_3$.

2. (Currently Amended) A compound having the structure of Formula XXXIV,



Formula XXXIV

their a pharmaceutically acceptable salt salts, pharmaceutically acceptable solvates, ~~enantiomers~~, diastereomers enantiomer, diastereomer, or N-oxide, ~~N-oxides~~ wherein

R_1 is selected from: hydrogen; alkyl; alkenyl; alkynyl; cycloalkyl; cyano; nitro; amino; substituted amino; hydroxyl; alkoxy; aryloxy; COR' ; $COOR'$

(wherein R' can be hydrogen, alkyl, alkenyl, alkynyl, (un)saturated cycloalkyl, aryl, aralkyl, heterocyclyl, (heterocyclyl)alkyl, or (heteroaryl)alkyl);

aryl; aralkyl; heteroaryl; heterocyclyl; (heteroaryl) alkyl; (heterocyclyl) alkyl; $(CH_2)_{1-4}OR'$

(wherein R' is as defined above, but also including hydroxy);

$C(=O)NR_xR_y$

(wherein R_x and R_y can be independently selected from hydrogen, alkyl, C_{3-6} alkenyl, C_{3-6} alkynyl, (un)saturated cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl); or $(CH_2)_m-C(=O)R_3$ [wherein m is an integer in the range of 0-2 and R_3 can be optionally substituted R_p or R_q (wherein R_p can be a 4-12 membered (un)saturated monocyclic or bicyclic ring containing 1-4 heteroatom(s) selected from N, O and S wherein the ring can be attached to $(CH_2)_mC(=O)$ through N and R_q can be a 4-12 membered (un)saturated monocyclic

or bicyclic ring containing 0-4 heteroatom(s) selected from the group consisting of N, O and S wherein the ring can be attached to $(CH_2)_mC(=O)$ through C) and wherein the substituents of R_3 can be one or more of: alkyl, alkenyl, alkynyl, (un)saturated cycloalkyl, halogen, hydroxyl, alkoxy, aryloxy, nitro, cyano, amino, substituted amino, hydroxyalkyl, oxo, acyl, optionally substituted amino (wherein the substituents are selected from C_1 - C_6 alkyl, aryl, aralkyl, or cycloalkyl), aryl, carboxyl, alkaryl, carbamoyl, alkyl ether, $C(=O)NR_5R_6$ (wherein R_5 and R_6 are independently selected from hydrogen, alkyl, C_{3-6} alkenyl, C_{3-6} alkynyl, aryl, and aralkyl), optionally substituted monocyclic or bicyclic 4-12 membered carbocyclic ring system (wherein the optional substituent(s) is/are selected from alkyl, alkenyl, alkynyl, halogen, hydroxyl, and alkoxy), heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclalkyl];

R_4 is selected from: hydrogen; alkyl; halogen; cyano; carboxy; or $C(=O)NR_xR_y$ wherein R_x and R_y are the same as defined above;


X_1 and X_2 are independently selected from: hydrogen; alkyl; alkenyl; alkynyl; cycloalkyl; acyl; aryl; aralkyl; heteroaryl; heterocyclyl; (heteroaryl)alkyl; or (heterocyclalkyl);

Y is selected from: an oxygen atom; a sulphur atom; or NR


(wherein R is selected from hydrogen, alkyl, alkenyl, alkynyl, un(saturated) cycloalkyl, acyl, aryl, aralkyl, heteroaryl, heterocyclyl, (heteroaryl)alkyl, or (heterocyclalkyl);

Y_1 and Y_2 are independently selected from: hydrogen; alkyl; nitro; cyano; halogen; OR wherein R is the same as defined earlier; SR wherein R is the same as defined earlier; NHR wherein R is the same as defined earlier; $COOR'$; or COR' wherein R' is the same as defined above, or further, Y_1 and X_2 , X_1 and Y_2 , X_1 and X_2 may together form a ring fused with the ring A containing 3-5 carbon atoms within the ring and having 1-3 heteroatoms selected from N, O or S; and

R_{19} represents $-CONHNH_2$, or



3. (Currently Amended) The compound of claim 1 having the structure of Formula XXXII,



Formula XXXII

their a pharmaceutically acceptable salt salts, pharmaceutically acceptable solvates, enantiomers, diastereomers enantiomer, diastereomer, or N-oxide, N-oxides wherein

R₁ is selected from: hydrogen; alkyl; alkenyl; alkynyl; cycloalkyl; cyano; nitro; amino; substituted amino; hydroxyl; alkoxy; aryloxy; COR'; COOR'

(wherein R' can be hydrogen, alkyl, alkenyl, alkynyl, (un)saturated cycloalkyl, aryl, aralkyl, heterocyclyl, (heterocyclyl)alkyl, or (heteroaryl)alkyl);

aryl; aralkyl; heteroaryl; heterocyclyl; (heteroaryl) alkyl; (heterocyclyl) alkyl; (CH₂)₁₋₄OR'

(wherein R' is as defined above, but also including hydroxy);

C(=O)NR_xR_y

(wherein R_x and R_y can be independently selected from hydrogen, alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, (un)saturated cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl); or (CH₂)_m-C(=O)R₃ [wherein m is an integer in the range of 0-2 and R₃ can be optionally substituted R_p or R_q (wherein R_p can be a 4-12 membered (un)saturated monocyclic or bicyclic ring containing 1-4 heteroatom(s) selected from N, O and S wherein the ring can be attached to (CH₂)_mC(=O) through N and R_q can be a 4-12 membered (un)saturated monocyclic or bicyclic ring containing 0-4 heteroatom(s) selected from the group consisting of N, O and S wherein the ring can be attached to (CH₂)_mC(=O) through C) and wherein the substituents of R₃ can be one or more of: alkyl, alkenyl, alkynyl, (un)saturated cycloalkyl, halogen, hydroxyl,

alkoxy, aryloxy, nitro, cyano, amino, substituted amino, hydroxyalkyl, oxo, acyl, optionally substituted amino (wherein the substituents are selected from C₁-C₆ alkyl, aryl, aralkyl, or cycloalkyl), aryl, carboxyl, alkaryl, carbamoyl, alkyl ether, C(=O)NR₅R₆ (wherein R₅ and R₆ are independently selected from hydrogen, alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, aryl, and aralkyl), optionally substituted monocyclic or bicyclic 4-12 membered carbocyclic ring system (wherein the optional substituent(s) is/are selected from alkyl, alkenyl, alkynyl, halogen, hydroxyl, and alkoxy), heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl];

R₄ is selected from: hydrogen; alkyl; halogen; cyano; carboxy; or C(=O)NR_xR_y wherein R_x and R_y are the same as defined above;

Y is selected from: an oxygen atom; a sulphur atom; or NR

(wherein R is selected from hydrogen, alkyl, alkenyl, alkynyl, un(saturated) cycloalkyl, acyl, aryl, aralkyl, heteroaryl, heterocyclyl, (heteroaryl)alkyl, or (heterocyclyl)alkyl);

Y₁ and Y₂ are independently selected from: hydrogen; alkyl; nitro; cyano; halogen; OR wherein R is the same as defined earlier; SR wherein R is the same as defined earlier; NHR wherein R is the same as defined earlier; COOR'; or COR' wherein R' is the same as defined above, or further, Y₁ and X₂, X₁ and Y₂, X₁ and X₂ may together form a ring fused with the ring A containing 3-5 carbon atoms within the ring and having 1-3 heteroatoms selected from N, O or S;


X₁ represents alkyl;

X₂ represents alkyl, cycloalkyl or aralkyl;

X₃, X₄, X₅ and X₆ independently represent C, CH, CH₂, CO, CS, NH, N, O, S; R₁₅, R₁₆, and R₁₇ independently represent no atom, alkyl, COCH₃, COOC₂H₅, NH₂, NH-cyclopropyl, CN, SH; and

---- represents an optional single bond.

4. (Currently Amended) The compound of claim 1 having the structure of Formula XXIII,



their a pharmaceutically acceptable salt salts, pharmaceutically acceptable solvates, enantiomers, diastereomers enantiomer, diastereomer, or N-oxide, N-oxides wherein

R₁ is selected from: hydrogen; alkyl; alkenyl; alkynyl; cycloalkyl; cyano; nitro; amino; substituted amino; hydroxyl; alkoxy; aryloxy; COR'; COOR'

(wherein R' can be hydrogen, alkyl, alkenyl, alkynyl, (un)saturated cycloalkyl, aryl, aralkyl, heterocyclyl, (heterocyclyl)alkyl, or (heteroaryl)alkyl);

aryl; aralkyl; heteroaryl; heterocyclyl; (heteroaryl) alkyl; (heterocyclyl) alkyl; (CH₂)₁₋₄OR'

(wherein R' is as defined above, but also including hydroxy);

C(=O)NR_xR_y

(wherein R_x and R_y can be independently selected from hydrogen, alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, (un)saturated cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl); or (CH₂)_m-C(=O)R₃ [wherein m is an integer in the range of 0-2 and R₃ can be optionally substituted R_p or R_q (wherein R_p can be a 4-12 membered (un)saturated monocyclic or bicyclic ring containing 1-4 heteroatom(s) selected from N, O and S wherein the ring can be attached to (CH₂)_mC(=O) through N and R_q can be a 4-12 membered (un)saturated monocyclic or bicyclic ring containing 0-4 heteroatom(s) selected from the group consisting of N, O and S wherein the ring can be attached to (CH₂)_mC(=O) through C) and wherein the substituents of R₃ can be one or more of: alkyl, alkenyl, alkynyl, (un)saturated cycloalkyl, halogen, hydroxyl,

alkoxy, aryloxy, nitro, cyano, amino, substituted amino, hydroxyalkyl, oxo, acyl, optionally substituted amino (wherein the substituents are selected from C₁-C₆ alkyl, aryl, aralkyl, or cycloalkyl), aryl, carboxyl, alkaryl, carbamoyl, alkyl ether, C(=O)NR₅R₆ (wherein R₅ and R₆ are independently selected from hydrogen, alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, aryl, and aralkyl), optionally substituted monocyclic or bicyclic 4-12 membered carbocyclic ring system (wherein the optional substituent(s) is/are selected from alkyl, alkenyl, alkynyl, halogen, hydroxyl, and alkoxy), heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclalkyl];

R₄ is selected from: hydrogen; alkyl; halogen; cyano; carboxy; or C(=O)NR_xR_y wherein R_x and R_y are the same as defined above;

X₁ and X₂ are independently selected from: hydrogen; alkyl; alkenyl; alkynyl; cycloalkyl; acyl; aryl; aralkyl; heteroaryl; heterocyclyl; (heteroaryl)alkyl; or (heterocyclalkyl);

Y is selected from: an oxygen atom; a sulphur atom; or NR

(wherein R is selected from hydrogen, alkyl, alkenyl, alkynyl, un(saturated) cycloalkyl, acyl, aryl, aralkyl, heteroaryl, heterocyclyl, (heteroaryl)alkyl, or (heterocyclalkyl);

Y₁ and Y₂ are independently selected from: hydrogen; alkyl; nitro; cyano; halogen; OR wherein R is the same as defined earlier; SR wherein R is the same as defined earlier; NHR wherein R is the same as defined earlier; COOR'; or COR' wherein R' is the same as defined above, or further, Y₁ and X₂, X₁ and Y₂, X₁ and X₂ may together form a ring fused with the ring A containing 3-5 carbon atoms within the ring and having 1-3 heteroatoms selected from N, O or S;

X₇ represents O or S; and

R₁₈ represents hydrogen, alkyl, aryl, heteroaryl, cycloalkyl or heterocyclalkyl.

5. (Original) The compound of claim 1 wherein R₂ is cyano.

6. (Original) The compound of claim 1 wherein R₂ is (CH₂)_nNHCOR₇, n represents an integer 1 to 6; and R₇ can represent hydrogen, alkyl, alkenyl, alkynyl, (un)saturated, cycloalkyl, alkoxy, aryloxy, aryl, aralkyl, heteroaryl, heterocyclalkyl, (CH₂)₁₋₄OR' wherein R' is the same as defined above, or NR_xR_y (wherein R_x and R_y can be independently selected from hydrogen,

alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, (un)saturated cycloalkyl, aryl, aralkyl, heteroaryl, heterocyclyl, heteroarylalkyl, or heterocyclylalkyl).

7. (Original) The compound of claim 1 wherein R₂ is 6-membered heteroaryl.
8. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
9. (Previously Cancelled)
10. (Previously Cancelled)
11. (Previously Cancelled)
12. (Previously Cancelled)
13. (Previously Cancelled)
14. (Previously Cancelled)
15. (Previously Cancelled)
16. (Previously Cancelled)
17. (Previously Cancelled)
18. (Previously Cancelled)
19. (Previously Cancelled)
20. (Previously Cancelled)
21. (Previously Cancelled)
22. (Previously Cancelled)
23. (Previously Cancelled)
24. (Previously Cancelled)
25. (Previously Cancelled)
26. (Previously Cancelled)

27. (Previously Cancelled)

28. (Previously Cancelled)